Switch to:
More From Other Websites
Goldman Sachs beats earnings estimates Oct 16 2014
Roche, Boehringer Drugs Wins Approval for Lung Disease Oct 15 2014
INTERMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Sep 29 2014
Roche purchases shares in tender offer for InterMune, Inc. Sep 29 2014
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action Sep 19 2014
Roche's $8 billion InterMune buy not a signal for more big deals Sep 16 2014
[video] Cramer: ACAD and ISIS have room to run Sep 11 2014
INTERMUNE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 05 2014
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015 Sep 05 2014
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action... Sep 03 2014
Lifshitz & Miller Law Firm Announces Investigation of China Housing & Land Development, Inc., Cobra... Sep 02 2014
Investor Lawsuit Against Takeover of InterMune Inc (ITMN) Announced by Shareholders Foundation Sep 02 2014
What You Need to Know About the Roche-InterMune Deal Aug 29 2014
[$$] An $8.3 Billion Rebuke to the FDA Aug 29 2014
Cramer: Sector could be hotbed of 'bolt-on' deals Aug 28 2014
InterMune downgraded by UBS Aug 28 2014
InterMune drug may offer big upside to Roche if aimed at liver Aug 27 2014
InterMune Stockholders Encouraged to Contact Securities Law Firm about Takeover Aug 27 2014
INTERMUNE SHAREHOLDER ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the... Aug 27 2014
INTERMUNE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating the Board of Directors of InterMune,... Aug 27 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK